[
  {
    "ts": "2025-12-06T19:00:00+00:00",
    "headline": "Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma",
    "summary": "SANTA MONICA, Calif., December 06, 2025--Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which continues to show clinically meaningful deep and durable efficacy with predictable and manageable safety observed to date in relapsed or refractory multiple myeloma (RRMM) patients who had received at least three prior lines of therapy. These ne",
    "url": "https://finance.yahoo.com/news/kite-announces-data-pivotal-immagine-190000714.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "185712ee-15de-307e-89d8-638ae38e62e0",
      "content": {
        "id": "185712ee-15de-307e-89d8-638ae38e62e0",
        "contentType": "STORY",
        "title": "Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma",
        "description": "",
        "summary": "SANTA MONICA, Calif., December 06, 2025--Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which continues to show clinically meaningful deep and durable efficacy with predictable and manageable safety observed to date in relapsed or refractory multiple myeloma (RRMM) patients who had received at least three prior lines of therapy. These ne",
        "pubDate": "2025-12-06T19:00:00Z",
        "displayTime": "2025-12-06T19:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/ac9c750e1a8315a701d5b553b879c794",
          "originalWidth": 1595,
          "originalHeight": 480,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oxs1m8XFuHFI3bswuGmcLA--~B/aD00ODA7dz0xNTk1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ac9c750e1a8315a701d5b553b879c794.cf.webp",
              "width": 1595,
              "height": 480,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oamV9XLOX_38oiB6VjxJsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ac9c750e1a8315a701d5b553b879c794.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/kite-announces-data-pivotal-immagine-190000714.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kite-announces-data-pivotal-immagine-190000714.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "ACLX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-06T19:00:00+00:00",
    "headline": "Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025",
    "summary": "SANTA MONICA, Calif., December 06, 2025--Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The results of the analysis were shared in an oral presentation (Abstract #265) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.",
    "url": "https://finance.yahoo.com/news/kite-next-generation-bicistronic-car-190000916.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "6ab7197c-8407-3c63-8b96-5576272d873d",
      "content": {
        "id": "6ab7197c-8407-3c63-8b96-5576272d873d",
        "contentType": "STORY",
        "title": "Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025",
        "description": "",
        "summary": "SANTA MONICA, Calif., December 06, 2025--Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The results of the analysis were shared in an oral presentation (Abstract #265) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.",
        "pubDate": "2025-12-06T19:00:00Z",
        "displayTime": "2025-12-06T19:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/5b76e8154a380d56790808aaa14be765",
          "originalWidth": 1595,
          "originalHeight": 480,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/i1YME9z46hUNVEUUdTUuMw--~B/aD00ODA7dz0xNTk1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/5b76e8154a380d56790808aaa14be765.cf.webp",
              "width": 1595,
              "height": 480,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.5CpZMgxTf0uqcLJz.BVEw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5b76e8154a380d56790808aaa14be765.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/kite-next-generation-bicistronic-car-190000916.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kite-next-generation-bicistronic-car-190000916.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]